Literature DB >> 19246700

Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke.

Anetta Undas1, Piotr Podolec, Krystyna Zawilska, Monika Pieculewicz, Ireneusz Jedliński, Ewa Stepień, Ewa Konarska-Kuszewska, Przemysław Weglarz, Malłgorzata Duszyńska, Ewelina Hanschke, Tadeusz Przewlocki, Wiesława Tracz.   

Abstract

BACKGROUND AND
PURPOSE: We tested the hypothesis that fibrin structure/function is unfavorably altered in patients with cryptogenic ischemic stroke.
METHODS: Ex vivo plasma fibrin clot permeability, turbidimetry, and efficiency of fibrinolysis were determined in 89 patients with patent foramen ovale (PFO) and a history of first-ever stroke, 58 patients with first-ever stroke and no PFO, and 120 healthy controls.
RESULTS: Stroke patients, evaluated 3 to 19 months after the event, and controls did not differ with regard to age, sex, smoking, and fibrinogen. Stroke patients with or without PFO had lower clot permeability (P<0.0001), faster fibrin polymerization (P<0.0001), prolonged clot lysis time (P<0.0001), higher maximum D-dimer levels released from clots (P<0.0001), and maximum rate of D-dimer release (P=0.02) than controls. Time from stroke occurrence showed no association with any clot variables. Scanning electron microscopy of fibrin clots showed increased fiber diameter and density in stroke patients. Clots from stroke patients with PFO were more permeable and showed shorter lysis time compared to those without PFO, and this was related to lower proportion of smokers in the former group.
CONCLUSIONS: Altered fibrin clot structure and resistance to fibrinolysis are associated with cryptogenic stroke.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246700     DOI: 10.1161/STROKEAHA.108.532812

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  29 in total

1.  Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.

Authors:  Piotr Mazur; Jacek Myć; Joanna Natorska; Krzysztof Plens; Dariusz Plicner; Grzegorz Grudzień; Bogusław Kapelak; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

2.  Nanoparticle diffusion measures bulk clot permeability.

Authors:  Richard Chasen Spero; Rachel K Sircar; Ryan Schubert; Russell M Taylor; Alisa S Wolberg; Richard Superfine
Journal:  Biophys J       Date:  2011-08-17       Impact factor: 4.033

3.  Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation.

Authors:  Emily P Mihalko; Megan Sandry; Nicholas Mininni; Kimberly Nellenbach; Halston Deal; Michael Daniele; Kamrouz Ghadimi; Jerrold H Levy; Ashley C Brown
Journal:  Blood Adv       Date:  2021-02-09

Review 4.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

Review 5.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

Review 6.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis.

Authors:  B L Walton; J R Byrnes; A S Wolberg
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

7.  Validation study toward measuring the mechanical properties of blood clots using resonant acoustic spectroscopy with optical vibrometry.

Authors:  Gongting Wu; Alisa S Wolberg; Amy L Oldenburg
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2012-02-28

8.  A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke.

Authors:  Etheresia Pretorius; Albe C Swanepoel; Hester M Oberholzer; Wendy J van der Spuy; Wiebren Duim; Pieter F Wessels
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

9.  Smoking out the cause of thrombosis.

Authors:  Robert A Campbell; Kellie R Machlus; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01       Impact factor: 8.311

10.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.